PharmacoEconomics

1997 - 2023

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 41, issue 6, 2023

The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice pp. 607-617

Bram Wouterse, Pieter Baal, Matthijs Versteegh and Werner Brouwer

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations pp. 619-632

Thomas Michael Otten, Sabine E. Grimm, Bram Ramaekers and Manuela A. Joore

Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review pp. 633-650

Olena Mandrik, Anne I. Hahn, James W. F. Catto, Ann G. Zauber, Marcus Cumberbatch and James Chilcott

Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review pp. 651-673

Yared Belete Belay, Lidia Engel, Yong Yi Lee, Ngoc Le and Cathrine Mihalopoulos

Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review pp. 675-692

Sean P. Gavan, Stuart J. Wright, Fiona Thistlethwaite and Katherine Payne

Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models pp. 693-707

Rebecca Giddings, Pitchaya Indravudh, Graham F. Medley, Fiammetta Bozzani, Mitzy Gafos, Shelly Malhotra, Fern Terris-Prestholt, Sergio Torres-Rueda and Matthew Quaife

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA pp. 709-718

Prajakta P. Masurkar, Haluk Damgacioglu, Ashish A. Deshmukh and Meghana V. Trivedi

Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031 pp. 719-732

Dina Abushanab, Clara Marquina, Jedidiah I. Morton, Daoud Al-Badriyeh, Melanie Lloyd, Dianna J. Magliano, Danny Liew and Zanfina Ademi

Volume 41, issue 5, 2023

Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review pp. 467-480

Fiammetta M. Bozzani, Fern Terris-Prestholt, Matthew Quaife, Mitzy Gafos, Pitchaya P. Indravudh, Rebecca Giddings, Graham F. Medley, Shelly Malhotra and Sergio Torres-Rueda

Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella pp. 481-497

Kris Doggen, Albert Jan van Hoek and Jeroen Luyten

Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review pp. 499-527

Emily R. Strouphauer, Olivia J. Morris, Keaton J. Soileau, Andrew D. Wiese, Troy Quast, Wayne K. Goodman, Sameer A. Sheth, Katharine D. Wojcik, Andrew G. Guzick and Eric A. Storch

HTA Barriers for Conditional Approval Drugs pp. 529-545

Mackenzie Mills

Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK pp. 547-559

Junwen Zhou, Runguo Wu, Claire Williams, Jonathan Emberson, Christina Reith, Anthony Keech, John Robson, Kenneth Wilkinson, Jane Armitage, Alastair Gray, John Simes, Colin Baigent and Borislava Mihaylova

How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes pp. 561-572

Valeska Hofbauer-Milan, Stefan Fetzer and Christian Hagist

The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight) pp. 573-587

Jacqueline Roseleur, David A. Gonzalez-Chica, Gillian Harvey, Nigel P. Stocks and Jonathan Karnon

Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan pp. 589-604

Taku Kobayashi, Masato Hoshi, Akira Yuasa, Shoko Arai, Mitsunobu Ikeda, Hiroyuki Matsuda, Seok-Won Kim and Toshifumi Hibi

Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US pp. 605-605

Hardik Goswami, Adnan Alsumali, Yiling Jiang, Matthias Schindler, Elizabeth R. Duke, Joshua Cohen, Andrew Briggs and Amy Puenpatom

Volume 41, issue 4, 2023

Modelling the Cost-Effectiveness of Diagnostic Tests pp. 339-351

Tristan Snowsill

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 353-361

Mohamed N. M. T. Al Khayat, Nigel Armstrong, Jeremy Howick, Susan O’Meara, Pawel Posadzki, Steve Ryder, Charlotte Ahmadu, Stefan R. A. Konings, Maarten J. Postma, Steven Duffy, Robert F. Wolff and Antoinette D. I. Asselt

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review pp. 363-391

Nannan Li, Charlotte Beaudart, Jane A. Cauley, Steven W. Ing, Nancy E. Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J. Singer and Mickaël Hiligsmann

Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review pp. 393-393

Nannan Li, Charlotte Beaudart, Jane A. Cauley, Steven W. Ing, Nancy E. Lane, Jean‑Yves Reginster, Stuart Silverman, Andrea J. Singer and Mickaël Hiligsmann

Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations pp. 395-411

Carina M. Behr, Martijn J. Oude Wolcherink, Maarten J. IJzerman, Rozemarijn Vliegenthart and Hendrik Koffijberg

Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario pp. 413-425

John J. Kim, Wasem Alsabbagh and William W. L. Wong

The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia pp. 427-438

Richard Norman, Brendan Mulhern, Emily Lancsar, Paula Lorgelly, Julie Ratcliffe, Deborah Street and Rosalie Viney

Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study pp. 439-455

Mengmeng Zhang, Yun Bao, Yi Yang, Melissa Kimber, Mitchell Levine and Feng Xie

Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis pp. 457-466

Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava, Alessandro Sasso, Thilo Schaufler, Marco Soro and James Fotheringham

Volume 41, issue 3, 2023

Living Health Technology Assessment: Issues, Challenges and Opportunities pp. 227-237

Praveen Thokala, Tushar Srivastava, Robert Smith, Shijie Ren, Melanie D. Whittington, Jamie Elvidge, Ruth Wong and Lesley Uttley

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 239-251

Antoinette D. I. Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M. Govers, Frank Hoentjen, Manuela A. Joore and Sabine E. Grimm

Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review pp. 253-273

Marie-Hélène Blanchet Zumofen, Jeff Frimpter and Svenn Alexander Hansen

Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review pp. 275-293

Erik Landfeldt, Sophia Abner, Astrid Pechmann, Thomas Sejersen, Hugh J. McMillan, Hanns Lochmüller and Janbernd Kirschner

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment pp. 295-306

Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang and Yun Lu

Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy pp. 307-319

Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen and Nai-Jung Chiang

Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? pp. 321-327

R. Brett McQueen, Kelly E. Anderson, Joseph F. Levy and Josh J. Carlson

The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned pp. 329-338

Sahar Al Shabasy, Bram Roudijk, Maggie Abbassi, Aureliano Finch, Elly Stolk and Samar Farid

Volume 41, issue 2, 2023

Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas pp. 119-121

J. Jaime Caro

How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe pp. 123-138

Tuba Saygın Avşar, Xiaozhe Yang and Paula Lorgelly

The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies pp. 139-153

Claire Lin, Xiaoyu Zhang and Huajie Jin

Psychometric Properties of Generic Preference-Weighted Measures for Children and Adolescents: A Systematic Review pp. 155-174

Rachel Lee-Yin Tan, Sonia Zhi Yi Soh, Le Ann Chen, Michael Herdman and Nan Luo

Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement pp. 175-186

Amy Gye, Stephen Goodall and Richard Abreu Lourenco

Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L pp. 187-198

Mona Aghdaee, Yuanyuan Gu, Kompal Sinha, Bonny Parkinson, Rajan Sharma and Henry Cutler

Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study pp. 199-207

Mónica Hernández Alava, Steve Pudney and Allan Wailoo

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy pp. 209-225

Carla Rognoni, Camilla Falivena, Francesco Costa and Patrizio Armeni

Volume 41, issue 1, 2023

Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial pp. 5-19

Nathan Green, Felicity Lamrock, Nichola Naylor, Jack Williams and Andrew Briggs

Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses pp. 21-32

Nichola R. Naylor, Jack Williams, Nathan Green, Felicity Lamrock and Andrew Briggs

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 33-42

Ben Wijnen, Willem Witlox, Robert Wolff, Debra Fayter, Bram Ramaekers, Thomas Otten, Steve Ryder, Pawel Posadzki, Gill Worthy, Lisa Stirk, Nigel Armstrong, Jos Kleijnen and Manuela Joore

Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments pp. 43-57

Shan Jiang, Ru Ren, Yuanyuan Gu, Varinder Jeet, Ping Liu and Shunping Li

The Costs of Dementia in Europe: An Updated Review and Meta-analysis pp. 59-75

Linus Jönsson, Ashley Tate, Oskar Frisell and Anders Wimo

Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures pp. 77-91

Siobhan Botwright, Ei Mon Win, Nattiya Kapol, Sirikanlaya Benjawan and Yot Teerawattananon

Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis pp. 93-105

Corneliu Bolbocean, Sylvia Pal, Stef Buuren, Peter J. Anderson, Peter Bartmann, Nicole Baumann, Jeanie L. Y. Cheong, Brian A. Darlow, Lex W. Doyle, Kari Anne I. Evensen, John Horwood, Marit S. Indredavik, Samantha Johnson, Neil Marlow, Marina Mendonça, Yanyan Ni, Dieter Wolke, Lianne Woodward, Erik Verrips and Stavros Petrou

Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service pp. 107-117

Pierluigi Russo, Matteo Zanuzzi, Angelica Carletto, Annalisa Sammarco, Federica Romano and Andrea Manca